FDA Approves AstraZeneca’s IMFINZI® (durvalumab) plus Chemotherapy to Treat Severe Types of Endometrial Cancer
AstraZeneca’s IMFINZI® (durvalumab) plus chemotherapy has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients struggling with mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer.
AstraZeneca’s IMFINZI® (durvalumab) plus chemotherapy has been approved by the US Food and Drug Administration (FDA) for the treatment of adult patients struggling with mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer.
